Skip to main content

본문내용

종목정보

종목토론카테고리

게시판버튼

게시글 제목

글쓰기 안되서..

작성자 정보

평민

게시글 정보

조회 431 2005/12/18 03:10

게시글 내용


Q&A: Cloned human embryos

People with heart conditions, Parkinson's, or spinal cord injuries could benefit
UK researchers have successfully made cloned human embryos, following in the steps of South Korean scientists who created 30 human embryo clones last year.
BBC News looks at the significance of the announcement.

What have the UK researchers done?

Professor Alison Murdoch and colleagues at Newcastle University took donor eggs and switched the genetic material of these cells with DNA from embryonic stem cells.

Three of the resultant clones grew for three days and one survived another two days.

Embryos at the five day stage are composed of a ball of cells and called a blastocyst.

How does this differ from the Seoul researchers' work?

Professor Hwang Woo-suk and colleagues created embryos that were the exact genetic copies of the women who donated the eggs and cells to make them.

They produced 30 embryo clones that divided over several days to a stage where special cells known as embryonic stem cells could be extracted.

How credible is the research?

Several groups have made claims in the past for similar work.

In some cases, no evidence was presented to back up the assertions. In others, where supporting data was published, the embryos stopped dividing at a very early stage.

The Koreans, on the other hand, have shown their embryos to be long lasting. What is more, they have subjected their work to independent scrutiny and a paper detailing their experiments has been published by the international journal Science.

Dr Murdoch's team's work is also published at Reproductive BioMedicine online

What makes these techniques successful?

Both the South Korean team and the UK researchers credit their successes to the use of extremely fresh donor eggs.

What is the point of the research?

SOUTH KOREAN CLONING



30 human embryos cloned
Cloning viewpoints

The ultimate aim would be to harvest stem cells - "master" cells that can divide into virtually any of the body's tissues - from the cloned embryos to treat diseases. This is known as therapeutic cloning.

The Koreans successfully extracted embryonic stem cells from their embryos.

They demonstrated the beginnings of this differentiation and saw it progress still further when the cells were transplanted into mice.

The Korean researchers view therapeutic cloning as very different from reproductive cloning - attempting to bring about the birth of a cloned baby.

How far away is therapeutic cloning?

Experts believe it will be many years before stem cell treatments based on cloning technology are available.

If the cells come from a cloned embryo they should not be rejected by the patient because they match exactly that individual's genetic make-up.

At the moment, patients have to take powerful drugs to prevent their body's immune system from attacking tissues transplanted from another person.

Are there not ethical concerns here?

All embryo research draws the criticism that it is tampering with cells which have the potential to be human beings.

The Korean and UK experiments were given approval by an ethical review board and all the women who donated cells and eggs gave informed consent - but this will mean nothing to those who are uncomfortable with this kind of science.

Could this latest work bring a cloned baby closer?

Potentially, yes.

Scientists have been struggling to clone monkeys. It is clear there are particular difficulties involved in making genetic copies of primates.

The Korean and UK research shows some of these technical hurdles can be overcome and those minded to produce cloned babies will attempt to use the new information to make children.




출처: http://news.bbc.co.uk/1/hi/sci/tech/3481159.stm



영어를 몰라사  해석은 못하는데여 영국에서 황박사님 논문으로 줄기세포 배양성공 / 이라나?

그럼 끝난거지뭐여..노가리가 돈에 눈이 멀어 헛소리하구 메디포스트와 합작?

게시글 찬성/반대

  • 1추천
  • 0반대
내 아이디와 비밀번호가 유출되었다? 자세히보기 →

운영배심원의견

운영배심원 의견?
운영배심원의견이란
운영배심원 의견이란?
게시판 활동 내용에 따라 매월 새롭게 선정되는
운영배심원(10인 이하)이 의견을 행사할 수 있습니다.

운영배심원 4인이 글 내리기에 의견을 행사하게 되면
해당 글의 추천수와 반대수를 비교하여 반대수가
추천수를 넘어서는 경우에는 해당 글이 블라인드 처리
됩니다.

댓글목록

댓글 작성하기

댓글쓰기 0 / 1000

게시판버튼

광고영역

하단영역

씽크풀 사이트에서 제공되는 정보는 오류 및 지연이 있을 수 있으며, 이를 기반으로 한 투자에는 손실이 발생할 수 있습니다.
그 이용에 따르는 책임은 이용자 본인에게 있습니다. 또한 이용자는 본 정보를 무단 복사, 전재 할 수 없습니다.

씽크풀은 정식 금융투자업자가 아닌 유사투자자문업자로 개별적인 투자상담과 자금운용이 불가합니다.
본서비스에서 제공되는 모든 정보는 투자판단의 참고자료로 원금 손실이 발생될 수 있으며, 그 손실은 투자자에게 귀속됩니다.

㈜씽크풀 서울시 영등포구 국제금융로 70, 15층 (여의도동, 미원빌딩)

고객센터 1666-6300 사업자 등록번호 116-81-54775 대표 : 김동진

Copyright since 1999 © ThinkPool Co.,Ltd. All Rights Reserved